StockDuty ← Dashboard Aug 17, 2026 01:34 PM ET
SignalCorporate

Leal Therapeutics Announces $30 Million Series A Extension and Initiation of Phase 1b/2a Clinical Trial of LTX-001 in Schizophrenia

$30M Series A extension and Phase 1b/2a trial initiation signal capital and clinical catalysts for LTX-001.

What changed
$30M Series A extension and Phase 1b/2a trial initiation signal capital and clinical catalysts for LTX-001.
Why it matters
$30M Series A extension and Phase 1b/2a trial initiation signal capital and clinical catalysts for LTX-001. — impact context not separately stored; see What changed.
Sources
eodhd
Related signals
FITCH AFFIRMS CHINA CREDIT RATING AT 'A' →FITCH ISSUES NEW STATEMENT AND OUTLOOK ON U.S . CREDIT RATING DEBT WARNING IN FIRST PARAGRAPH . →$FMX →